Evidence map›Paper›PMID 35286673›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Disruptors of AKAP-Dependent Protein-Protein Interactions.

Ryan Walker-Gray, Tamara Pallien, Duncan C Miller, Andreas Oder, Martin Neuenschwander, Jens Peter von Kries, Sebastian Diecke, Enno Klussmann

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ryan Walker-GrayMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Tamara PallienMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Duncan C MillerMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Andreas OderLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Martin NeuenschwanderLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Jens Peter von KriesLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Sebastian DieckeMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Enno KlussmannMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. enno.klussmann@mdc-berlin.de.ORCID 0000-0003-4004-5003
Max Delbrück Center · DELeibniz-Forschungsinstitut für Molekulare Pharmakologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A-kinase anchoring proteins (AKAPs) are a family of multivalent scaffolding proteins. They engage in direct protein-protein interactions with protein kinases, kinase substrates and further signaling molecules. Each AKAP interacts with a specific set of protein interaction partners and such sets can vary between different cellular compartments and cells. Thus, AKAPs can coordinate signal transduction processes spatially and temporally in defined cellular environments. AKAP-dependent protein-protein interactions are involved in a plethora of physiological processes, including processes in the cardiovascular, nervous, and immune system. Dysregulation of AKAPs and their interactions is associated with or causes widespread diseases, for example, cardiac diseases such as heart failure. However, there are profound shortcomings in understanding functions of specific AKAP-dependent protein-protein interactions. In part, this is due to the lack of agents for specifically targeting defined protein-protein interactions. Peptidic and non-peptidic inhibitors are invaluable molecular tools for elucidating the functions of AKAP-dependent protein-protein interactions. In addition, such interaction disruptors may pave the way to new concepts for the treatment of diseases where AKAP-dependent protein-protein interactions constitute potential drug targets.Here we describe screening approaches for the identification of small molecule disruptors of AKAP-dependent protein-protein interactions. Examples include interactions of AKAP18 and protein kinase A (PKA) and of AKAP-Lbc and RhoA. We discuss a homogenous time-resolved fluorescence (HTRF) and an AlphaScreen

Indexed as

A Kinase Anchor ProteinsInduced Pluripotent Stem CellsCyclic AMP-Dependent Protein KinasesHumansProtein BindingSignal TransductionA Kinase Anchor ProteinsCyclic AMP-Dependent Protein KinasesAKAP18AKAP-LbcA-kinase anchoring protein (AKAP)AlphaScreen®Calcium imagingHomogenous time-resolved fluorescence (HTRF) assayHuman induced pluripotent stem cells (hiPSCs)Inhibitory peptidesLine scan imagingNon-peptidic helix mimeticsProtein kinase A (PKA)Small molecules

Identifiers

PMID35286673
OpenAlexW4225988882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.